BioCryst Pharma (BCRX) Tops Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $9.31 +1.86%
Revenue Growth %: +13.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Revenue Growth %: +13.7%
Financial Fact:
Net loss: -11.53M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $71.47 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Morgan Stanley upgrades CDW on stronger AI-driven server demand
- MSCI acquires First Street for $120M to expand climate risk data
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
